REVEAL研究设计:124I-evuzamitide PET/CT诊断心脏淀粉样变性
REVEAL是一项多中心3期开放标签单臂研究,评估124I-evuzamitide PET/CT在疑似心脏淀粉样变性(CA)患者中的诊断性能。研究在美国18个中心入组成人患者,以盲法判读的PET/CT心肌摄取与盲法裁决的标准诊疗诊断对比,主要终点为敏感性和特异性。
要点
- REVEAL为首个评估纤维靶向PET放射性示踪剂诊断CA的多中心3期研究。
- 124I-evuzamitide靶向淀粉样纤维中超硫酸化硫酸乙酰肝素聚糖,可结合多种淀粉样亚型。
- 主要终点为视觉判读PET/CT诊断CA的敏感性和特异性,对照盲法裁决的标准诊疗诊断。
核心结论
- REVEAL是首个评估纤维靶向PET放射性示踪剂诊断CA的多中心3期研究,可能建立无创分子影像方法检测多种淀粉样亚型的心脏和全身淀粉样沉积。
研究设计与样本
- 开放标签、单臂研究,在美国18个中心入组疑似CA的成人患者。
- 排除既往诊断CA或已知器官受累的系统性淀粉样变性、使用前体蛋白靶向治疗、eGFR低于15 mL/min/1.73 m2、近期心肌梗死或近期肝素暴露者。
- 静脉给予124I-evuzamitide(1.0 ± 0.1 mCi)后4 ± 1小时行心脏和部分身体静态PET/CT显像,并给予碘化钾减少甲状腺对游离放射性碘的摄取。
- 三名盲法专家医师独立视觉评估PET/CT心肌示踪剂摄取;另三名盲法淀粉样变性专家基于标准诊疗临床、实验室、活检、遗传、心电图、超声心动图、心脏磁共振和骨亲和示踪剂心脏闪烁显像数据裁决CA存在与否。
关键数值与推荐
- 主要终点为视觉判读124I-evuzamitide PET/CT诊断CA的敏感性和特异性,对照盲法裁决的标准诊疗诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this study is to describe the rationale and design of the multicenter phase 3 Research with EVuzamitide to Evaluate for cardiac AmyLoidosis (REVEAL) trial evaluating the diagnostic performance of 124I-evuzamitide positron emission tomography/computed tomography (PET/CT) for detection of cardiac amyloidosis (CA) in patients undergoing evaluation for suspected disease. 124I-evuzamitide is a novel fibril-targeting positron-emitting radiotracer that binds hypersulfated heparan sulfate glycans in amyloid fibrils across multiple amyloid subtypes. METHODS: This open-label, single-arm study, enrolled adults with suspected CA at 18 USA centers. Participants with previously diagnosed CA or systemic amyloidosis with known organ involvement, precursor protein targeted therapy use, estimated glomerular filtration rate less than 15 mL/min/1.73 m2, recent myocardial infarction, or recent heparin exposure were excluded. Cardiac and partial-body static PET/CT imaging was performed 4 ± 1 hour after intravenous administration of 124I-evuzamitide (1.0 ± 0.1 mCi). Potassium iodide was administered to reduce thyroid uptake of free radioiodine. Three blinded expert physicians independently assessed myocardial tracer uptake visually on PET/CT scans. Separately, three blinded amyloidosis experts adjudicated the presence or absence of CA using standard-of-care clinical, laboratory, biopsy, genetic, electrocardiographic, echocardiographic, cardiac magnetic resonance, and bone-avid tracer cardiac scintigraphy data. The primary endpoints were the sensitivity and specificity of visually interpreted 124I-evuzamitide PET/CT for the diagnosis of CA compared with the adjudicated standard-of-care diagnosis. CONCLUSIONS: REVEAL is the first multicenter phase 3 study evaluating a fibril-targeted PET radiotracer for the diagnosis of CA and may establish a noninvasive molecular imaging approach for detecting cardiac and systemic amyloid deposition across multiple amyloid subtypes.
引用
- Dorbala S, Maurer MS, Cuddy SAM, et al. Design and rationale of the Research with EVuzamitide to Evaluate for cardiac AmyLoidosis (REVEAL) positron emission tomography study: A study of 124I-evuzamitide to diagnose cardiac amyloidosis. J Nucl Cardiol. 2026. PMID: 42297126. doi:10.1016/j.nuclcard.2026.102773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。